Effectiveness of Vaccines Booster Against Infection, Severe Disease and Death Related to COVID-19 : A Systematic Review and Meta-Analysis
Downloads
COVID-19 is an infectious disease as a result of a kind of corona virus. COVID-19 is now a pandemic affecting many countries. This study aims to know the effectiveness of booster vaccines to reduce the severity of illness, confirm infection, hospitalization, death in humans infected with COVID-19. For Specific purpose, to analyze the severity of COVID-19 disease in humans by booster and without booster. The design of this study was a systematic review and meta-analysis based on observational studies, published in databases such as Pubmed, Embase, MedRxiv, Nature and Scopus. In the search for articles, the limitations of 2021 to 2022 are used. This research was analyzed quantitatively through the Review Manager 5.4.1 program. Study was taken from 13 journals that met the criteria for a meta-analysis. With the population aged over 18 years, and using the type of vaccine BNT162b2 or mRNA. The population of this study came from Israel, Italy, England, Qatar, Brazil, Turkey, Puerto-Rico, Northern Bangkok, Vicinities and Thailand. Significant results were obtained for each outcome. The OR values of BNT162b2 booster vaccine against confirmed infection OR 0.16 (95% CI 0.06 – 0.45), against symptomatic disease 0.22 (95% CI 0.11 – 0.44), against asymptomatic disease OR 0.72 (95% CI 0.69 – 0.74), against hospitalization OR 0.12 (95% CI 0.06 – 0.22), against severe disease OR 0.15 (95% CI 0.07 – 0.33), and against death OR 0.10 (95% CI 0.04 – 0.31). Administration booster vaccines is effective in reducing infection rates, disease severity, and deaths from COVID-19.
WHO. Coronavirus disease (COVID-19): Vaccines. 2022.
WHO. Coronavirus. 2022.
Åžimşek-Yavuz S, Komsuoğlu Çelikyurt FI. An update of anti-viral treatment of COVID-19. Turkish J Med Sci. 2021 Dec;51(SI-1):3372–90.
Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020 Sep;130(9):4791–7.
Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, et al. Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. Am J Pathol. 2020 Aug;190(8):1680–90.
6. WHO. Enhancing response to Omicron SARS-CoV-2 variant. 2022.
Burhan E, Rachmadi RA. Omicron surge and the future of COVID-19 vaccinations. Med J Indones. 2022;31(1):80–4.
Joung SY, Ebinger JE, Sun N, Liu Y, Wu M, Tang AB, et al. Awareness of SARS-CoV-2 Omicron Variant Infection among Adults with Recent COVID-19 Seropositivity. JAMA Netw Open. 2022;5(8):E2227241.
Aggarwal A, Mehta S, Gupta D, Sheikh S, Pallagatti S, Singh R, et al. Clinical & immunological erythematosus patients characteristics in systemic lupus Maryam. J Dent Educ [Internet]. 2012;76(11):1532–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23144490
GA Wells, B Shea, D O'Connell, J Peterson, V Welch, M Losos PT. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2021.
PRISMA. PRISMA Flow Diagram. 2020.
Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty. 2021;10(1):132.
Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022;114:252–60.
Muhsen K, Maimon N, Mizrahi A, Varticovschi B, Bodenheimer O, Gelbshtein U, et al. Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel. N Engl J Med. 2022;386(4):399–401.
Spitzer A, Angel Y, Marudi O, Zeltser D, Saiag E, Goldshmidt H, et al. Association of a Third Dose of BNT162b2 Vaccine with Incidence of SARS-CoV-2 Infection among Health Care Workers in Israel. JAMA - J Am Med Assoc. 2022;327(4):341–9.
Mattiuzzi C, Lippi G. Primary COVID-19 vaccine cycle and booster doses efficacy: analysis of Italian nationwide vaccination campaign. Eur J Public Health. 2022;1–12.
Mattiuzzi C, Lippi G. Efficacy of COVID-19 vaccine booster doses in older people. Eur Geriatr Med. 2022;
Berec L, Å míd M, PÅ™ibylová L, Májek O, Pavlík T, Jarkovskí½ J, et al. Real-life protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in the Czech Republic: A whole country retrospective view. medRxiv. L. Berec, Centre for Mathematical Biology, Institute of Mathematics, Faculty of Science, University of South Bohemia, BraniÅ¡ovská 1760, ÄŒeské BudÄ›jovice, Czech Republic; 2021.
Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Alroy-Preis S, et al. Protection Across Age Groups of BNT162b2 Vaccine Booster against Covid-19. medRxiv. 2021 Jan;2021.10.07.21264626.
Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393–400.
Andrews N, Stowe J, Kirsebom F, Gower C, Ramsay M, Bernal JL. Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study. medRxiv. 2021 Jan;2021.11.15.21266341.
Abu-raddad LJ, Chemaitelly H, Ayoub HH. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters. 2022;
Cerqueira-Silva T, Katikireddi S V, de Araujo Oliveira V, Flores-Ortiz R, Júnior JB, Paixí£o ES, et al. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nat Med. 2022;
Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al. Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England. Nat Med. 2022;
Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;
Uzun O, Akpolat T, Varol A, Turan S, Bektas SG, Cetinkaya PD, et al. COVID-19: vaccination vs. hospitalization. Infection. 2022;
Robles-Fontán MM, Irizarry RA. Effectiveness of different booster regimens for preventing infection and adverse outcomes in Puerto Rico. medRxiv. R.A. Irizarry, Dana-Farber Cancer Institute,; 2021.
Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, Damronglerd P, Suwantarat N, Satdhabudha A, et al. Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study. Emerg microbes & Infect. 2022;11(1):585–92.
Arbel R, Hammerman A, Sergienko R, Friger M, Peretz A, Netzer D, et al. BNT162B2 vaccine booster and mortality due to covid-19. N Engl J Med. 2021;385(26):2413–20.
Omer SB, Malani PN. Booster Vaccination to Prevent COVID-19 in the Era of Omicron: An Effective Part of a Layered Public Health Approach. Vol. 327, JAMA. United States; 2022. p. 628–9.
Glatman-Freedman A, Bromberg M, Hershkovitz Y, Sefty H, Kaufman Z, Dichtiar R, Keinan-Boker L. Effectiveness of BNT162b2 vaccine booster against SARS-CoV-2 infection and breakthrough complications, Israel. Emerging infectious diseases. 2022; 28(5), 948.
Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Ackerson BK, et al. Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study. Lancet Reg Heal Am. 2022 Feb;100198.
Tsang, NNY, So, HC, Cowling BJ, Leung GM, Ip DKM. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA. 2 in Hong Kong: a prospective cohort study. The Lancet Infectious Diseases. 2022; 23(4), 421-434.
Doria-Rose NA, Shen X, Schmidt SD, O'Dell S, McDanal C, Feng W, et al. Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization. medRxiv : the preprint server for health sciences. 2021.
Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N Engl J Med. 2021;385(16):1474–84.
Thompson MG, Burgess JL, Naleway AL et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers ” Eight U.S. Locations, December 2020–March. MMWR Morb Mortal Wkly Rep 2021. 2021.
Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, Aug. MMWR Morb Mortal Wkly Rep. 2022;71(7):255–63.
Copyright (c) 2024 Indonesian Journal of Tropical and Infectious Disease
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
